VIDEO: Reduction of vascular leakage, hyperreflective foci greater with faricimab

Issue: March 25, 2024

ByJordan M. Graff, MD, FACS

BySara Kellner

Fact checked byChristine Klimanskis, ELS

WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Jordan M. Graff, MD, FACS, describes a post hoc analysis of the YOSEMITE and RHINE clinical trials evaluating biomarkers for vascular stability.

The trials evaluated faricimab vs. aflibercept in patients with diabetic macular edema.

“In summary, we follow these markers for vascular stability and found in this subset analysis of YOSEMITE and RHINE a greater reduction in hyperreflective foci as well as greater reduction in the vascular leakage [with faricimab],” Graff said.

Published by:

Sources/Disclosures

Collapse

Source:

Graff JM. Biomarkers for vascular stability and inflammation demonstrate the benefit of dual Ang-2/VEGF-A inhibition with faricimab phase 3 trials in DME. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.

Disclosures: Graff reports receiving research support from Genentech and Regeneron.

Hawaiian Eye/Retina Meeting

Read more

VIDEO: Reduction of vascular leakage, hyperreflective foci greater with faricimab

Related Content